Diagnostic problems in Huntington's chorea and tardive dyskinesia.
نویسنده
چکیده
W HEN THE CLINICIAN encounters a demented adult patient with choreiform movements he is likely to think of the diagnosis of Huntington’s chorea. However, when the family is inconclusive and the patient has been medicated with neuroleptic agents, the diagnosis of tardive dyskinesia, the late and frequently permanent complication of neuroleptics, must also be considered. How confidently can this differential diagnosis be made? An answer to this question will be sought by reviewing and comparing (1) the significant epidemiologic data, (2) the clinical descriptions, (3) the psychologic symptomatology, (4) associated drug use, (5) the speculated pathophysiologic mechanisms, (6) the presumptive pharmacologic diagnostic tests, (7) the neurochemical findings, (8) the radiographic and postmortem findings, and (9) other findings of both Huntington’s chorea and tardive dyskinesia. The following case history illustrates the difficulty that is sometimes encountered when attempting to differentiate between Huntington’s chorea and tardive dyskinesia.
منابع مشابه
Missing Huntington's disease for tardive dyskinesia: a preventable error.
Distinguishing spontaneous from drug induced involuntary movements in a patient with psychiatric illness can be a diagnostic challenge to clinicians. Tardive dyskinesia (TD) is a common drug induced movement disorder in such patients but Huntington’s disease (HD) also manifests itself with spontaneous abnormal movements and psychiatric abnormalities.1 Patients with a psychiatric presentation of...
متن کاملA double blind trial of sulpiride in Huntington's disease and tardive dyskinesia.
Eleven patients with Huntington's disease and nine patients with tardive dyskinesia participated in a randomised double-blind crossover trial of sulpiride (as sole antidopaminergic therapy) versus placebo. Although functional improvement was not seen in Huntington's disease patients, sulpiride reduced movement count and total dyskinesia score in both conditions. Sulpiride differs pharmacologica...
متن کاملTetrabenazine, depression and suicide: good news.
Tetrabenzaine, (XenzineTM, Lundbeck) a reversible inhibitor of vesicular monoamine transporter 2, is thus far the only drug approved by the FDA specifically for Huntington’s disease. The target symptom is chorea, with a mechanism of action related to its capacity to deplete monoamines [1]. Tetrabenazine has been available since the 1950’s, and had been repeatedly shown in large case series to b...
متن کاملNeuroleptic Malignant Syndrome Induced by Olanzapine in a Patient with Huntington's Disease.
Olanzapine is an atypical antipsychotic that binds to a large number of neurotransmitter receptors, including the dopamine D1, D2, and D4, serotonin and histamine receptors. Its antipsychotic effects are likely the result of potent antagonism at dopamine and serotonin receptors [1]. It is frequently used in Huntington’s disease (HD) since it reduces chorea, is a mood stabilizer, augments antide...
متن کاملAn investigation on the relationship between risk factors and severity of tardive dyskinesia
The focus of most previous research concerning tardive dyskinesia has been on the impact of risk factors on the development( incidence) of this syndrome. In this paper, we report our results on the relationship between risk factors and the severity of tardive dyskinesia. A total of 33 patients diagnosed as tardive dyskinesia with no other medical illness studied: 21 males and 12 females with a ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Comprehensive psychiatry
دوره 17 2 شماره
صفحات -
تاریخ انتشار 1976